Luciani Giovanni Battista, Cullurà Gianluca, Segreto Antonio, Ardigò Andrea, Hoxha Stiljan, Rossetti Lucia, Prioli Maria Antonia, Faggian Giuseppe
Division of Cardiac Surgery, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy.
Division of Cardiac Surgery, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy.
Semin Thorac Cardiovasc Surg. 2023 Spring;35(1):115-124. doi: 10.1053/j.semtcvs.2021.11.019. Epub 2022 Mar 25.
To define current role of the Ross operation in young patients, the outcome in those followed longer than 20 years were assessed. Between 1994 and 2020, 81 consecutive patients, 70 of 11 male and/or female, mean age 27 years underwent Ross procedure, accruing 20 years of follow-up or longer. Sixty-four had bicuspid valve (79%) and 54 (67%) aortic insufficiency, while 15 (19%) had undergone prior operations. Surgery consisted in root replacement in 53 patients, cylinder inclusion in 20 and sub-coronary graft in 8. There were 7 late deaths in 80 hospital survivors (median follow-up 21 years, IQR 20-23), with 88% ± 5% survival at 25 years. Thirty-four patients required left, 6 left and/or right and 1 right heart valve reoperation, on average 13 years after Ross procedure. Reoperation was valve-sparing in 18 (45%) patients and valve and/or root replacement in 22. Ten (24%) reoperated patients required a second reoperation 18 years after Ross procedure. Freedom from autograft reoperation was 46% ± 6%, while from autograft valve replacement was 60% ± 7%, thanks to autograft valve-sparing. Freedom from isolated right valve reoperation was 98% ± 4%. No mortality was associated with any of the 51 reoperations. Root technique was associated with reoperation (P = 0.024). Age at follow-up was 50 years (IQR 36-60), with 70 (96%) patients in NYHA class I and 6 (55%) women carrying out pregnancies. Young patients undergoing the Ross procedure enjoy unprecedented survival well into the third decade of follow-up, even when faced with reoperation. At 25 years risk of autograft reoperation is consistent, while negligible for homograft. Technical improvements at operation and valve-sparing at reoperation may prolong autograft valve durability.
为明确罗斯手术在年轻患者中的当前作用,我们评估了随访时间超过20年的患者的手术结果。1994年至2020年期间,连续81例患者(男11例和/或女70例,平均年龄27岁)接受了罗斯手术,随访时间累积达20年或更长。64例患者为二叶式瓣膜(79%),54例(67%)有主动脉瓣关闭不全,15例(19%)曾接受过先前手术。手术方式包括53例患者行根部置换,20例患者行柱状植入,8例患者行冠状动脉下移植。80例住院幸存者中有7例晚期死亡(中位随访时间21年,四分位间距20 - 23年),25年生存率为88%±5%。34例患者需要进行左心瓣膜再次手术,6例患者需要进行左心和/或右心瓣膜再次手术,1例患者需要进行右心瓣膜再次手术,平均在罗斯手术后13年。18例(45%)患者再次手术时保留了瓣膜,22例患者进行了瓣膜和/或根部置换。10例(24%)再次手术的患者在罗斯手术后18年需要进行第二次再次手术。由于保留了自体瓣膜,自体瓣膜再次手术的自由度为46%±6%,自体瓣膜置换的自由度为60%±7%。孤立性右心瓣膜再次手术的自由度为98%±4%。51次再次手术均未导致死亡。根部技术与再次手术相关(P = 0.024)。随访时的年龄为50岁(四分位间距36 - 60岁),70例(96%)患者为纽约心脏协会心功能I级,6例(55%)女性怀孕。接受罗斯手术的年轻患者在随访的第三个十年中享有前所未有的生存率,即使面临再次手术也是如此。25年时自体瓣膜再次手术的风险是一致的,而异体瓣膜的风险可忽略不计。手术技术的改进和再次手术时保留瓣膜可能会延长自体瓣膜的耐久性。